tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ORIC Stock Latest News

Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
The FlyOric Pharmaceuticals initiated with an Outperform at Evercore ISI
1d ago
ORIC
Promising Potential of Oric Pharmaceuticals’ ORIC-944 in Prostate Cancer Market Drives Buy Rating
PremiumRatings
Promising Potential of Oric Pharmaceuticals’ ORIC-944 in Prostate Cancer Market Drives Buy Rating
1d ago
ORIC
Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan
PremiumThe Fly
Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan
3d ago
ORIC
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
PremiumThe Fly
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
4d ago
ORIC
Oric Pharmaceuticals price target raised to $16 from $12 at Citi
PremiumThe Fly
Oric Pharmaceuticals price target raised to $16 from $12 at Citi
4d ago
ORIC
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
PremiumCompany AnnouncementsOric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
5d ago
ORIC
Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
Premium
Ratings
Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
7d ago
ORIC
Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
Premium
The Fly
Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
7d ago
ORIC
Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals
PremiumRatings
Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals
7d ago
ORIC
Oric Pharmaceuticals price target raised to $15 from $12 at Oppenheimer
PremiumThe Fly
Oric Pharmaceuticals price target raised to $15 from $12 at Oppenheimer
7d ago
ORIC
Oric Pharmaceuticals price target lowered to $19 from $20 at Wells Fargo
PremiumThe Fly
Oric Pharmaceuticals price target lowered to $19 from $20 at Wells Fargo
7d ago
ORIC
ORIC Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
ORIC Pharmaceuticals Reports Q3 2025 Financial Results
7d ago
ORIC
Oric Pharmaceuticals announces completion of dose exploration for ORIC-944
PremiumThe FlyOric Pharmaceuticals announces completion of dose exploration for ORIC-944
8d ago
ORIC
Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results
Premium
Company Announcements
Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results
8d ago
8K
ORIC
Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)
Premium
The Fly
Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)
8d ago
ORIC
Is ORIC a Buy, Before Earnings?
PremiumPre-Earnings
Is ORIC a Buy, Before Earnings?
13d ago
ORIC
Promising Preclinical Data and Strategic Combinations Bolster Buy Rating for ORIC-944
PremiumRatings
Promising Preclinical Data and Strategic Combinations Bolster Buy Rating for ORIC-944
24d ago
ORIC
Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer
PremiumCompany Announcements
Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer
25d ago
ORIC
Oric Pharmaceuticals’ Promising Study on ORIC-114 for Solid Tumors
PremiumCompany Announcements
Oric Pharmaceuticals’ Promising Study on ORIC-114 for Solid Tumors
25d ago
ORIC
Oric Pharmaceuticals Advances in NSCLC Treatment with Phase 1b Study
PremiumCompany AnnouncementsOric Pharmaceuticals Advances in NSCLC Treatment with Phase 1b Study
25d ago
ORIC
Oric Pharmaceuticals presents posters at EORTC-NCI-AACR on ORIC-944
Premium
The Fly
Oric Pharmaceuticals presents posters at EORTC-NCI-AACR on ORIC-944
25d ago
ORIC
Promising Outlook for Oric Pharmaceuticals: Buy Rating Backed by Prostate Cancer Program Developments and Strong Financial Position
Premium
Ratings
Promising Outlook for Oric Pharmaceuticals: Buy Rating Backed by Prostate Cancer Program Developments and Strong Financial Position
1M ago
ORIC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >